Oracle
ORCL
Vale SA
VALE
Toll Brothers
TOL
4
D.R. Horton
DHI
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
FATE Fate Therapeutics
- 1.250
- -0.030-2.34%
Close Apr 28 16:00 ET
- 1.250
- 0.0000.00%
Post 16:20 ET
143.25MMarket Cap-0.76P/E (TTM)
1.310High1.230Low1.14MVolume1.280Open1.280Pre Close1.44MTurnover1.14%Turnover RatioLossP/E (Static)114.60MShares5.92052wk High0.45P/B125.12MFloat Cap0.66152wk Low--Dividend TTM100.10MShs Float121.160Historical High--Div YieldTTM6.25%Amplitude0.661Historical Low1.263Avg Price1Lot Size
About Fate Therapeutics Company
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Company Profile
SymbolFATE
Company NameFate Therapeutics
Listing DateOct 1, 2013
Issue Price6.00
Founded2007
CEODr. Bahram Valamehr, M.B.A.,PhD
MarketNASDAQ
Employees181
Fiscal Year Ends12-31
Address12278 Scripps Summit Drive
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92131
Phone1-858-875-1800
Company Executives
- Name
- Position
- Salary
- Dr. Bahram Valamehr, M.B.A.,PhD
- Director, President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
- 3.58M
- Cindy R. Tahl, J.D.
- Chief Legal and Compliance Officer and Corporate Secretary
- 3.42M
- Dr. William H. Rastetter,PhD
- Chairman of the Board
- 197.42K
- Dr. John D. Mendlein, J.D.,PhD
- Vice Chairman of the Board
- 160.92K
- Timothy P. Coughlin
- Independent Director
- 175.92K
- Michael Lee
- Independent Director
- 160.92K
- Matthew C. Abernethy
- Independent Director
- --
- Dr. Yuan Xu, PhD
- Independent Director
- 166.92K
- Dr. Shefali Agarwal, M.D.,M.P.H.
- Independent Director
- 171.92K
- Dr. Robert S. Epstein, M.D.,M.S.
- Independent Director
- 172.42K
- Dr. Neelufar Mozaffarian, F.A.C.R.,M.D.,PhD
- Independent Director
- 358.40K
- Dr. Karin Jooss, PhD
- Independent Director
- 172.92K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call